SyntheticMR Valuation

Q: What is the Fair Price of 9480 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

9480 (€0.97) is trading below our estimate of [[fair value]] (€33.42)

Is 9480 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 9480 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 9480 (€0.97) is trading below our estimate of fair value (€33.42)

Significantly Below Fair Value: 9480 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 9480?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for 9480. This is calculated by dividing 9480's market cap by their current preferred multiple.
What is 9480's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	SEK 1.15b

9480 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	13.1x
Enterprise Value/EBITDA	163.2x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does 9480's PB Ratio compare to its peers?

The above table shows the PB ratio for 9480 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	2.1x
M3V MeVis Medical Solutions	2.4x	n/a	€42.2m
AJ91 DocCheck	1.2x	n/a	€43.1m
COP CompuGroup Medical SE KGaA	1.2x	27.5%	€740.3m
NXU Nexus	3.6x	16.9%	€940.9m
9480 SyntheticMR	n/a	89.0%	€1.2b

Price-To-Book vs Peers: Insufficient data to calculate 9480's Price-To-Book Ratio vs. peers for valuation analysis.

Price to Earnings Ratio vs Industry

How does 9480's PE Ratio compare vs other companies in the European Healthcare Services Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	25.8%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	25.8%
	n/a	n/a	n/a

No more companies

Price-To-Book vs Industry: Insufficient data to calculate 9480's Price-To-Book Ratio vs. industry for valuation analysis.

Price to Book Ratio vs Fair Ratio

What is 9480's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

9480 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	n/a
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 9480's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 9480 forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	n/a	€1.63 0%	2.7%	€1.67	€1.59	n/a	2
Sep ’25	€1.12	€1.63 +46.2%	2.7%	€1.67	€1.59	n/a	2
Aug ’25	€1.30	€1.62 +25.1%	2.7%	€1.66	€1.58	n/a	2
Jul ’25	n/a	€3.14 0%	12.7%	€3.54	€2.74	n/a	2

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.